TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06845241: A Multi-center, Non-randomized, and Open-label Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 68 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,796,480

Rescue Site Savings

+$5,811,960

Unlock Full NCT06845241 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06845241 Rescue Dossier →